![]() | |
![]()
Skeletal formula and ball-and-stick model of defactinib
| |
Clinical data | |
---|---|
Other names | PF-04554878, VS-6063 |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H21F3N8O3S |
Molar mass | 510.50 g·mol−1 |
3D model (JSmol) | |
| |
|
Defactinib (INN, codenamed VS-6063) is an inhibitorofPTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors.
Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial.[1][2] Subsequent research in patients with specific NF2 mutations also found limited activity.[3]
As of 2022, it remains in trials in combination with other medications for other types of cancer.
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |